Mashup Score: 0 Sanofi: Press Releases, Tuesday, May 31, 2022 - 2 year(s) ago Read the latest news about our company Source: https://www.sanofi.com/en/media-room/press-releases/2022/2022-05-31-07-00-00-2452848 Categories: Dermatology, Latest Headlines Tweet Tweets with this article JCADermatology The @US_FDA has approved @Dupixent® (dupilumab) for priority review in adults with prurigo nodularis. If approved, #Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. https://t.co/QETS1pJzcI
The @US_FDA has approved @Dupixent® (dupilumab) for priority review in adults with prurigo nodularis. If approved, #Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. https://t.co/QETS1pJzcI